Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / Mar / Single Test Boosts Childhood Cancer Care
Oncology Genetics and epigenetics Screening and monitoring Oncology Molecular Pathology

Single Test Boosts Childhood Cancer Care

A new approach sees improved diagnosis and treatment selection for children with cancer

By George Francis Lee 03/15/2022 Quick Read (pre 2022) 1 min read

Share

Mutation analysis in oncology is a fast-growing field – but some mutations are trickier than others. Gene fusions present a challenge due to the rarity of individual fusions, the potential for atypical breakpoints, and promiscuous fusion partners. Nonetheless, it’s believed that gene fusions play a role in up to 20 percent of all human cancers (1). In fact, several childhood cancers, including leukemias, lymphomas, and sarcomas, are distinguished by their potential for gene fusions. Accurate detection of these mutations is vital for effective patient care – and that’s why a research team in the Netherlands has employed a method of RNA sequencing using the whole transcriptome in a bid to improve diagnostic accuracy.

The results stem from the Princess Máxima Center for Pediatric Oncology, which has increased its identification of relevant tumor characteristics by almost 40 percent since adopting whole transcriptome RNA sequencing for all of their patients (2). Using the new approach, the researchers were able to identify 83 fusions within 244 patients, 24 of which were missed by traditional methods and seven of which modified the original diagnosis or treatment. And, although standard diagnostics identified many of the same fusion genes, the identification was often just one half of the two-sided fusion, yielding an incomplete picture.

“RNA sequencing was already used before, but only in children who were very ill, and for whom standard treatment had stopped working,” said study co-author Bastiaan Tops (3). “In our research hospital setting at the Princess Máxima Center, we have implemented RNA sequencing into standard diagnostics. Our new study shows that this approach is paying off.”

Whole transcriptome RNA sequencing is not without its disadvantages – most significantly, that the ideal sample size is 300 ng of RNA (with a minimum of at least 50 ng), whereas traditional methods such as RT-PCR require as little as 10 ng. Nonetheless, the study authors encountered insufficient sample volume or quality in only 3 percent of cases, making this a minor issue relative to the clinical benefits offered by whole transcriptome RNA sequencing.

Hero & Teaser Image Credit: Muhammed Zafer Yahsi on Unsplash.com

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. F Mitelman et al., Nat Rev Cancer, 7, 233 (2007). PMID: 17361217.
  2. JY Hehir-Kwa et al., JCO Precision Oncology, 6, e2000504 (2022). PMID: 35085008.
  3. Princess Máxima Center (2022). Available at: https://bit.ly/3ttZcHo.

About the Author(s)

George Francis Lee

Interested in how disease interacts with our world. Writing stories covering subjects like politics, society, and climate change.

More Articles by George Francis Lee

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.